Sight Sciences, Inc. SGHT

Company Overview

Sight Sciences, Inc. is a U.S.-based medical technology company focused on ophthalmology, with a primary emphasis on interventional glaucoma treatment and dry eye disease management. The company develops and commercializes minimally invasive technologies intended to address underlying causes of chronic eye diseases rather than relying exclusively on pharmaceutical therapies. Sight Sciences operates within the broader medical device and ophthalmic healthcare industries, serving ophthalmologists, ambulatory surgery centers, and eye care clinics.

The company’s principal revenue drivers are its interventional glaucoma products, including the OMNI Surgical System and SION Surgical Instrument, as well as its dry eye treatment platform, TearCare. Sight Sciences positions itself within the growing minimally invasive glaucoma surgery (MIGS) market and the procedural dry eye treatment segment, emphasizing physician adoption, procedural efficiency, and disease intervention earlier in the treatment continuum. Founded in 2011, the company evolved from a glaucoma-focused device developer into a broader ophthalmic platform company through internal product development and commercialization expansion.

Business Operations

Sight Sciences primarily generates revenue through the sale of ophthalmic surgical and procedural devices used in glaucoma and dry eye treatment. Its operations are generally organized around two core commercial areas: Glaucoma and Dry Eye. The glaucoma business centers on canal-based surgical intervention technologies designed to restore physiological aqueous humor outflow in patients with open-angle glaucoma. The dry eye business focuses on thermal eyelid treatment technology intended to address meibomian gland dysfunction, a common underlying cause of evaporative dry eye disease.

The company operates primarily in the United States while also pursuing selective international commercialization opportunities through distributors and strategic channel relationships. Sight Sciences controls proprietary device technologies, intellectual property related to ophthalmic intervention systems, and clinical data supporting physician adoption. The company has historically emphasized direct commercialization infrastructure, physician training programs, reimbursement expansion efforts, and clinical evidence generation as central operational components. Public disclosures indicate ongoing collaboration with eye care providers and surgical centers rather than reliance on large-scale pharmaceutical partnerships.

Strategic Position & Investments

Sight Sciences’ strategic direction has centered on expanding adoption of interventional ophthalmic procedures that can be integrated earlier in disease management pathways. The company has invested heavily in clinical research, reimbursement support initiatives, physician education, and commercial expansion for both glaucoma and dry eye products. Its strategy reflects broader industry trends favoring minimally invasive procedures and device-based alternatives to long-term pharmaceutical management in ophthalmology.

The company has also pursued growth through product iteration and platform development rather than large-scale acquisition activity. Key strategic assets include the OMNI Surgical System, which combines canaloplasty and trabeculotomy capabilities in a single device platform, and the TearCare System, which targets procedural dry eye treatment in office-based settings. Sight Sciences has positioned itself within emerging procedural ophthalmology segments where demographic trends, aging populations, and increasing prevalence of chronic eye disease may support long-term demand growth. Data regarding major joint ventures or significant portfolio company investments is limited in publicly available disclosures.

Geographic Footprint

Sight Sciences is headquartered in Menlo Park, California, and derives the majority of its revenue from the United States market. Its commercial presence is concentrated in U.S. ophthalmology practices, ambulatory surgical centers, and hospital-affiliated eye care systems. The company has emphasized physician-focused commercial operations and reimbursement engagement within the domestic healthcare market.

Internationally, Sight Sciences has pursued more selective market participation through distribution relationships and regulatory clearances in certain non-U.S. jurisdictions. Public filings and company disclosures indicate exposure to markets in parts of Europe, Asia-Pacific, and other international regions, although international revenue remains substantially smaller than domestic operations. The company’s operational influence internationally is primarily tied to commercialization and distribution activities rather than extensive manufacturing or regional infrastructure buildouts.

Leadership & Governance

Sight Sciences was co-founded by ophthalmic device entrepreneurs and has maintained a management focus on interventional eye care innovation, clinical adoption, and physician-centric product development. Corporate governance and strategic execution have emphasized commercialization discipline, evidence-based product positioning, and expansion within procedural ophthalmology markets.

Key executives include:

• Paul Badawi – Co-Founder and Chief Executive Officer
• David Badawi – Co-Founder and Chief Technology Officer
• Krish Krishnan – President and Chief Operating Officer
• Brice McKibbin – Chief Financial Officer

The company’s leadership philosophy, as reflected in public filings and investor communications, has focused on transforming ophthalmic care through procedural intervention technologies designed to improve clinical outcomes and reduce dependence on chronic medication-based management.